This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.
A Phase 1, single centre, open-label study of TLX592 to assess the safety and tolerability, pharmacokinetics, biodistribution and radiation dosimetry in patients diagnosed with prostate cancer.
|Eligibility criteria|| |
|Study details|| |
This research study will be examining a new product for identifying and in the future potentially treating prostate cancer. This new product targets PSMA on tumour cells. The product is an antibody-based pharmaceutical and is called 64Cu-TLX592 (or TLX592). 64Cu-TLX592 is an antibody which has been specifically designed to clear rapidly from your bloodstream. As a result of more rapid clearance from the bloodstream, 64Cu-TLX592 is expected to have less uptake in key organs, which may help develop new therapies with improved safety while maintaining the anti-cancer effects.
The aim of this study is to determine the effect of three different increasing doses on the biodistribution and pharmacokinetics of 64Cu-TLX592 – which will assist in evaluating any potential risks associated with this new pharmaceutical.
|Further information|| |
For more information regarding this clinical trial click here.